IO Biotech (IOBTQ) AI Stock Analysis

Top Page

IO Biotech

(Other OTC:IOBTQ)

Select Model

Rating:40.65Neutral

Price Target:$0.30▲(2910.00% Upside)

Action:reiterated

Date:01/31/26

The score is primarily driven lower by weak financial performance (pre-revenue, large losses, substantial cash burn, and sharply thinner equity cushion) and bearish technicals (price below all major moving averages with negative MACD). Corporate events further increase downside and financing/listing risk, while valuation metrics provide limited offset due to negative earnings and no dividend.

Positive Factors

Proprietary discovery platformA validated IO Discovery platform that identifies tumor-associated antigens is a durable competitive asset. It can continually generate new vaccine candidates, support combination strategies across indications, and increase the firm's attractiveness for partnerships or licensing agreements over time.

Negative Factors

Pre-revenue with heavy cash burnBeing pre-revenue with ~ $88M TTM net losses and material operating cash burn is a persistent structural weakness. It necessitates recurring financing, increases dilution risk, and constrains the firm's ability to sustain multiple clinical programs without securing additional capital or partnerships.

IO Biotech (IOBTQ) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $885.69K
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -0.0
Beta (1Y): -9.13
Revenue Growth: ―
EPS Growth: ―
Country: US
Employees: 80
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

IO Biotech Business Overview & Revenue Model

Company Description

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive protein...

How the Company Makes Money

IO Biotech is a clinical-stage company and does not have publicly available information indicating product sales revenue. Historically, its cash inflows have primarily come from financing activities (e.g., issuing equity in public or private offering...

IO Biotech Financial Statement Overview

Summary

Very weak fundamentals for a development-stage biotech: zero revenue and large ongoing losses (TTM net loss ~$88.3M) alongside heavy cash burn (TTM operating cash flow and FCF about -$81M). Balance sheet resilience has deteriorated sharply in TTM with equity near ~$0.9M and higher leverage (debt-to-equity ~1.60), increasing funding and dilution risk.

Income Statement

12Very Negative

Balance Sheet

28Negative

Cash Flow

10Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Mar 2022	Dec 2020
Income Statement
Total Revenue	0	0	0	0	0	0
Gross Profit	-910.00K	-849.00K	-756.00K	-540.00K	0	0
EBITDA	-87.25M	-93.20M	-84.47M	-69.34M	-67.45M	-12.02M
Net Income	-88.35M	-95.49M	-86.08M	-71.46M	-67.88M	-12.04M
Balance Sheet
Total Assets	39.96M	67.70M	150.72M	151.81M	222.29M	5.65M
Cash, Cash Equivalents and Short-Term Investments	30.66M	60.03M	143.19M	142.59M	211.53M	3.40M
Total Debt	1.46M	1.92M	2.49M	2.79M	0	0
Total Liabilities	39.05M	20.68M	17.56M	12.95M	10.36M	3.05M
Stockholders Equity	911.00K	47.02M	133.16M	138.85M	211.92M	2.60M
Cash Flow
Free Cash Flow	-81.06M	-82.39M	-72.06M	-60.42M	-40.80M	-9.96M
Operating Cash Flow	-81.00M	-82.35M	-71.74M	-59.73M	-40.65M	-9.96M
Investing Cash Flow	-69.00K	-44.00K	-323.00K	-690.00K	-153.00K	0
Financing Cash Flow	32.76M	0	71.86M	0	252.95M	5.10M

IO Biotech Technical Analysis

Technical Analysis SentimentNegative

Last Price0.01

Price Trends

50DMA0.25Negative

100DMA0.45Negative

200DMA0.93Negative

Market Momentum

MACD-0.07Positive

RSI20.74Positive

STOCH3.65Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IOBTQ, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.13, below the 50-day MA of 0.25, and below the 200-day MA of 0.93, indicating a bearish trend. The MACD of -0.07 indicates Positive momentum. The RSI at 20.74 is Positive, neither overbought nor oversold. The STOCH value of 3.65 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IOBTQ.

IO Biotech Risk Analysis

IO Biotech disclosed 89 risk factors in its most recent earnings report. IO Biotech reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

1 New Risk

1.The biopharmaceutical industry is subject to extensive regulatory obligations and policies that are subject to change, including due to judicial challenges.Q3, 2024

IO Biotech Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

IOBTQ against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EVAX	49Neutral	$24.44M	-0.48	-61.39%	―	134.15%	82.33%
IGC	42Neutral	$21.49M	-2.25	-113.58%	―	―	―
IOBTQ	41Neutral	$7,195	-0.01	-465.36%	―	―	―
ELUT	40Underperform	$37.07M	0.64	940.81%	―	-48.76%	-3.02%
PLUR	27Underperform	$15.64M	-0.51	144.63%	―	-23.95%	30.12%

* Healthcare Sector Average

Performance Comparison

IOBTQ and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IOBTQ	Io Biotech, Inc.	0.01	-0.90	-98.90%
IGC	Igc Pharma, Inc.	0.18	-0.22	-53.98%
PLUR	Pluri Inc.	1.24	-2.45	-66.40%
ELUT	Elutia Inc.	0.84	-0.10	-10.48%
EVAX	Evaxion Biotech A/S Adr	2.93	-2.84	-49.22%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Jan 31, 2026

IO Biotech AI Stock Analysis